Register
Login:
Share:
Email Facebook Twitter


Tech company Mporium delivers an outstanding set of Q1 results says CEO De Groot
IronRidge Resources CEO hails spectacular lithium project and money making potential for gold




Share Price Information for Shield Thera (STX)


Share Price: 81.50Bid: 81.00Ask: 82.00Change: 0.00 (0.00%)No Movement on Shield Thera
Spread: 1.00Spread as %: 1.23%Open: 77.50High: 0.00Low: 0.00Yesterday’s Close: 81.50

Shield Therapeutics Plc Ord 1.5P






Share Price SpacerPrice
81.50
Share Price SpacerBid
81.00
Share Price SpacerAsk
82.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
0
Share Price SpacerOpen
77.50
Share Price SpacerHigh
0.00
Share Price SpacerLow
0.00
Share Price SpacerClose
81.50
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 116.82m £95.21m 2,000

52 Week High 83.00 52 Week High Date 15-APR-2019
52 Week Low 15.10 52 Week Low Date 1-MAY-2018

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
0 0 0 -4.794 -17.00 0.00 0.00


London South East Users info for Shield Thera




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

18-Apr-19
16:28:41
81.70
6,416
Buy* 
81.00
82.00
5,242
Trade Type:
Ordinary

18-Apr-19
16:25:40
80.75
15,000
Sell* 
81.00
82.00
12.11k
Trade Type:
Ordinary

18-Apr-19
16:21:42
81.00
5,000
Sell* 
81.00
82.00
4,050
Trade Type:
Ordinary




View more Shield Thera trades >>

Directors Deals for Shield Thera (STX)
Trade DateActionNotifierPriceCurrencyAmountHolding
16-Apr-19Buy
Trade Notifier Information for Shield Therapeutics
James M Karis held the position of Non-Executive Chairman at Shield Therapeutics at the time of this trade.
 James M Karis
81GBX4,00086667
16-Apr-19Exercise of option
Trade Notifier Information for Shield Therapeutics
Carl Sterritt held the position of CEO at Shield Therapeutics at the time of this trade.
 Carl Sterritt
1.5GBX123,69010198951
15-Apr-19Buy
Trade Notifier Information for Shield Therapeutics
James M Karis held the position of Non-Executive Chairman at Shield Therapeutics at the time of this trade.
 James M Karis
81.5GBX46,00086667
View more Shield Thera directors dealings >>


GoldenDust
Posts: 14
Opinion:No Opinion
Price:81.00
RE: 15p-75p in 1 yr - still on the rise
Sat 16:14
Yes, now 81p.

Looks like sp will continue rising into the July pdufa date.

If successful with New Drug Approval in the US, as seems probable, given the fact the drug is already widely available in Europe, Shield will seek a licensing deal with a US partner similar to the very good one done in Europe in September.

Given the attractive market cap, sensible money would be on Shield getting taken out for a high premium on the sp at that time. If there were any competition in the bidding process, given projected revenues over the patented period we would likely be looking at Shield being taken out for a multiple of the share price at some point later this year.
Tatty99
Posts: 107
Opinion:No Opinion
Price:81.50
RE: 15p-75p in 1 yr - still on the rise
12 Apr '19
And so it continues. 80p broken
GoldenDust
Posts: 14
Opinion:No Opinion
Price:75.50
15p-75p in 1 yr - still on the rise
5 Apr '19
STX continues to rise and with a pdufa date in July you have to expect that looking at its current market cap it will double again before then. Similar stage companies in the US are valued around 0.5bn and STX still under 0.1bn.
ennombrede
Posts: 193
Premium Chat Member
Opinion:No Opinion
Price:76.00
Outlook Thoughts
2 Apr '19
. Feraccru is material to Norgine and its salespeople are paid commission on sales
. Royalties of 25% to 40%
. STX cost base will stay low, and co is fully funded according to biz plans for the foreseeable assuming a US deal
. US Royalties maybe in the teens %
. These Revs will flow straight to bottom line once corp. costs covered.
. Feraccru sales targeting >$1bn pa
. CEO & Founder retains sizable equity interest

We'll maybe get to learn a little more tomorrow about progress
notrac
Posts: 353
Opinion:No Opinion
Price:68.00
Jumps on change of adviser
1 Apr '19
Financial results are due on Wed. There was a large buy this morning. Float is small. Perhaps they have discovered a leak.
View more share chat for Shield Thera (STX) >>







Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk











Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.